Ampio

Vasaloc™ for Diabetic Nephropathy

Vasaloc^™ will be developed as an existing oral drug that will be a new treatment for diabetic nephropathy - a progressive complication of diabetes that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis. Current treatment that includes controlling blood sugar, hypertension, blood lipids, etc. can help slow, but not stop, the progression toward ESRD. Vasaloc^™ is a repositioned compound based on a low-dose formulation of the approved drug, danazol. As this compound is also formulated in Optina^™, we will evaluate Vasaloc^™ for further clinical trials after completion and evaluation of the Optina^™ trial.

« back to products page